1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013

Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 116 pages

Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). Skin And Skin Structure Infections (SSSI) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI).
- A review of the Skin And Skin Structure Infections (SSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Skin And Skin Structure Infections (SSSI) - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Skin And Skin Structure Infections (SSSI) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) 9
Skin And Skin Structure Infections (SSSI) Therapeutics under Development by Companies 11
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Skin And Skin Structure Infections (SSSI) Therapeutics - Products under Development by Companies 18
Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development 20
GlaxoSmithKline plc 20
Takeda Pharmaceutical Company Limited 21
Rib-X Pharmaceuticals, Inc. 22
Paratek Pharmaceuticals, Inc. 23
Affinium Pharmaceuticals, Inc. 24
Basilea Pharmaceutica Ltd. 25
CrystalGenomics, Inc. 26
PolyMedix, Inc. 27
Bharat Biotech International Limited 28
Nabriva Therapeutics AG 29
Cempra Pharmaceuticals, Inc. 30
Trius Therapeutics, Inc. 31
Tetraphase Pharmaceuticals Inc. 32
Durata Therapeutics Inc. 33
Skin And Skin Structure Infections (SSSI) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
dalbavancin - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
GSK-1322322 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
AFN-1252 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
lysostaphin - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
ceftaroline fosamil - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
omadacycline tosylate - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
brilacidin - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
BC-3781 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
BC-7013 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
delafloxacin - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
radezolid - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
radezolid - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
CG-400549 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
oritavancin disphosphate - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
fusidic acid - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
tedizolid phosphate - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
faropenem medoxomil - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
avarofloxacin - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
ABI-0043 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
eravacycline - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
ceftobiprole medocaril - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
CF-301 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
Bismith-Thiol Compund For Acute Wound Infection - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
Skin And Skin Structure Infections (SSSI) Therapeutics - Drug Profile Updates 80
Skin And Skin Structure Infections (SSSI) Therapeutics - Discontinued Products 105
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 106
Skin And Skin Structure Infections (SSSI) - Product Development Milestones 107
Featured News and Press Releases 107
Nov 16, 2012: PolyMedix Announces Successful Meeting With FDA For Brilacidin 107
Oct 25, 2012: Durata Therapeutics Completes Target Enrollment In Phase III Study Comparing Dalbavancin To Vancomycin And Linezolid In ABSSSI Patients 107
Oct 19, 2012: Trius Presents Clinical Data On Antibiotic Drug Candidate Tedizolid At IDWeek 2012 108
Oct 18, 2012: Durata Therapeutics Presents Results From Skin Lesion Measurement Study Of Dalbavancin At IDWeek 2012 108
Oct 16, 2012: Trius Therapeutics To Present Data From Tedizolid Clinical Studies At IDWeek Conference 109
Oct 10, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Radezolid 110
Oct 04, 2012: Durata Therapeutics To Present Two Abstracts Concerning Dalbavancin At IDWeek 2012 111
Sep 17, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Delafloxacin 111
Sep 11, 2012: Durata Therapeutics Announces Completion Of QT Study Of Dalbavancin 112
Sep 11, 2012: Rib-X Pharma Presents Data From Multiple Radezolid Studies At ICAAC 2012 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 116
Disclaimer 116



List of Tables

Number of Products Under Development for Skin And Skin Structure Infections (SSSI), H1 2013 9
Products under Development for Skin And Skin Structure Infections (SSSI) - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Development by Companies, H1 2013 (Contd..1) 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Development by Companies, H1 2013 (Contd..1) 19
GlaxoSmithKline plc, H1 2013 20
Takeda Pharmaceutical Company Limited, H1 2013 21
Rib-X Pharmaceuticals, Inc., H1 2013 22
Paratek Pharmaceuticals, Inc., H1 2013 23
Affinium Pharmaceuticals, Inc., H1 2013 24
Basilea Pharmaceutica Ltd., H1 2013 25
CrystalGenomics, Inc., H1 2013 26
PolyMedix, Inc., H1 2013 27
Bharat Biotech International Limited, H1 2013 28
Nabriva Therapeutics AG, H1 2013 29
Cempra Pharmaceuticals, Inc., H1 2013 30
Trius Therapeutics, Inc., H1 2013 31
Tetraphase Pharmaceuticals Inc., H1 2013 32
Durata Therapeutics Inc., H1 2013 33
Assessment by Monotherapy Products, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 38
Skin And Skin Structure Infections (SSSI) Therapeutics - Drug Profile Updates 80
Skin And Skin Structure Infections (SSSI) Therapeutics - Discontinued Products 105
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 106



List of Figures

Number of Products under Development for Skin And Skin Structure Infections (SSSI), H1 2013 9
Products under Development for Skin And Skin Structure Infections (SSSI) - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 34
Assessment by Route of Administration, H1 2013 35
Assessment by Stage and Route of Administration, H1 2013 36
Assessment by Molecule Type, H1 2013 37
Assessment by Stage and Molecule Type, H1 2013 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.